Global Dolutegravir and Dolutegravir Generic Drugs Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Global Dolutegravir and Dolutegravir Generic Drugs Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030

Dolutegravir belongs to a class of drugs called integrase inhibitors, which are used in combination with other drugs to treat HIV infection. It helps reduce the amount of HIV in the body, allowing a person's immune system to function better. This reduces the chance of HIV complications (e.g., new infections, cancer) and improves quality of life. Dolutegravir is given to adults and children 4 weeks of age and weighing at least 6 pounds (3 kilograms). Generic drugs are identical to brand-name drugs in dosage, safety, effectiveness, strength, stability, quality, and how to take them. Generic drugs tend to cost less than brand-name drugs. The goal of generic dolutegravir is to provide innovative drug formulations for the treatment and prevention of AIDS to people living with HIV in developing countries on an affordable and sustainable basis.

Market Overview:

The latest research study on the global Dolutegravir and Dolutegravir Generic Drugs market finds that the global Dolutegravir and Dolutegravir Generic Drugs market reached a value of USD 2936.23 million in 2023. It’s expected that the market will achieve USD 4349.53 million by 2029, exhibiting a CAGR of 6.77% during the forecast period.

Rising global prevalence of HIV/AIDS

Acquired immunodeficiency syndrome (AIDS) is a potentially life-threatening chronic disease caused by the human immunodeficiency virus (HIV). HIV interferes with the body's ability to fight infection and disease by damaging the immune system. HIV is a sexually transmitted infection (STI). The disease can also be spread through contact with infected blood and illegal injection drugs or by sharing needles, and from mother to child during pregnancy, childbirth or breastfeeding. According to the World Health Organization, HIV remains a major global public health problem, continuing to spread in all countries around the world and claiming 40.4 million [32.9 million-51.3 million] lives to date. At the end of 2022, there were an estimated 39 million [33.1 million-45.7 million] people living with HIV, two-thirds of them (25.6 million) in the WHO African Region. In 2022, 630,000 [480,000-880,000] people will die from HIV-related causes and 1.3 million [1 million-1.7 million] people will be infected with HIV. As the number of HIV-positive people rises sharply, this will drive the growth of dolutegravir and dolutegravir generic drugs industry.

Effectiveness in treating HIV/AIDS

Dolutegravir and generic dolutegravir belong to a class of drugs called HIV integrase inhibitors. It works by reducing the amount of HIV in the blood and increasing the number of immune cells that help fight infections in the body. Dolutegravir is very effective at quickly suppressing someone's viral load (the number of copies of HIV in the blood). This is important for the long-term health of the person taking it. An undetectable viral load also means a person can no longer transmit HIV to other people. In clinical trials, patients taking dolutegravir reported significantly fewer side effects than those taking efavirenz (EFV). This includes reducing central nervous system side effects such as depression and anxiety. Improved tolerability of dolutegravir should make it easier to adhere to treatment in the long term. Additionally, dolutegravir has fewer drug interactions and has a higher genetic barrier to resistance compared with EFV. Therefore, this will boost the dolutegravir and dolutegravir generics market due to its effectiveness in treating HIV/AIDS.

Region Overview:

In 2022, the share of the Dolutegravir and Dolutegravir Generic Drugs market in United States stood at 38.44%.

Company Overview:

The major players operating in the Dolutegravir and Dolutegravir Generic Drugs market include ViiV Healthcare Pty Ltd, Viatris, Emcure Pharmaceuticals, Aurobindo Pharma, Cipla, etc. Among which, ViiV Healthcare Pty Ltd ranked top in terms of sales and revenue in 2023.

ViiV Healthcare is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS.

Segmentation Overview:

By type, 50mg Tablets segment accounted for the largest share of market in 2022.

Application Overview:

By application, the Adult segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Dolutegravir and Dolutegravir Generic Drugs market covered in Chapter 3:

Emcure Pharmaceuticals
Aurobindo Pharma
ViiV Healthcare Pty Ltd
Cipla
Viatris
Hetero

In Chapter 4 and Chapter 14.2, on the basis of types, the Dolutegravir and Dolutegravir Generic Drugs market from 2019 to 2030 is primarily split into:

5mg Tablets
50mg Tablets

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Dolutegravir and Dolutegravir Generic Drugs market from 2019 to 2030 covers:

Children
Adult

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)